Mixed glioblastoma multiforme and sarcoma. A clinicopathologic study of 26 radiation therapy oncology group cases
نویسندگان
چکیده
منابع مشابه
Radiothermotherapy for glioblastoma multiforme: A preliminary study
Introduction: Glioblastoma multiforme (GBM) is a highly radioresistant cancer with low survival rate. Current therapy approaches have failed to treat GBM. The aim of this study was to assess how GBM tumors respond to combination of hyperthermia and radiotherapy. Materials and Methods: In this study, 38 GBM patients were included. 19 patients were treated ...
متن کاملEpithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group.
Epithelioid sarcoma (ES) is rare with a poor prognosis and for which a loss of INI1 expression has been recently reported. We report a study of 106 cases with clinical, histologic, and immunohistochemical data, including INI1 expression, and follow-up data. Of the 106 cases, 70 were the conventional subtype and 36 the large cell subtype. INI1 was negative in 86 cases (81.1%): 57 (81%) of 70 con...
متن کاملValidation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma.
PURPOSE Previous recursive partitioning analysis (RPA) of patients with malignant glioma (glioblastoma multiforme [GBM] and anaplastic astrocytoma [AA]) produced six prognostic groups (I-VI) classified by six factors. We sought here to determine whether the classification for GBM could be improved by using an updated Radiation Therapy Oncology Group (RTOG) GBM database excluding AA and by consi...
متن کاملViral therapy of glioblastoma multiforme.
Of all human malignancies, glioblastoma multiforme (GBM) is among the most refractory to existing therapies despite combination approaches of surgical resection, irradiation, and chemotherapy. The median survival is ∼12–14 mo, regardless of the therapeutic intervention. The 5-y survival of patients with a diagnosis of GBM is less than 9.8% (1). This remarkably poor rate of survival begs the que...
متن کاملEnzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.
We conducted a phase I study to determine the safety and recommended phase II dose of enzastaurin (oral inhibitor of the protein kinase C-beta [PKCbeta] and the PI3K/AKT pathways) when given in combination with radiation therapy (RT) plus temozolomide to patients with newly diagnosed glioblastoma multiforme or gliosarcoma. Patients with Karnofsky performance status > or =60 and no enzyme-induci...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 1991
ISSN: 0008-543X,1097-0142
DOI: 10.1002/1097-0142(19910501)67:9<2342::aid-cncr2820670922>3.0.co;2-b